Amgen "outperform"

03/03/06 - Robert W. Baird

NEW YORK, March 3 (newratings.com) - Analysts at Robert W Baird reiterate their "outperform" rating on Amgen Inc (AMGN). The target price is set to $90.

In a research note published this morning, the analysts mention that recent nephrology market data indicates the widespread use of erythropoietin (EPO) in chronic kidney disease (CKD) patients. There is significant growth potential for Amgen’s Aranesp in CKD patients in the near to medium term, the analysts say. The drug is expected to gain market share from Procrit in 2006, Robert W Baird adds.